97073 ⎘
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans Apolipopeptides
Peptide epitopes of apolipoprotein B
#302Peptide epitopes of apolipoprotein B
#303Peptide epitopes of apolipoprotein B
#304Peptide derivatives, preparation and uses thereof
#305Muteins of human lipocalin 2 (LcnC,hNGAL) with affinity for a given target
#306CATION AND ANION EXCHANGE CHROMATOGRAPHY METHOD
#307Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
#308RECOMBINANT APOA-1M FROM ENGINEERED BACTERIA
#309BLADDER CANCER BIOMARKER AND TEST METHOD USING THE SAME
#310APOE PEPTIDE DIMERS AND USES THEREOF
#311Potent and selective mediators of cholesterol efflux
#312TRPM-2 antisense therapy
#313Production of Therapeutic Proteins in Photosynthetic Organisms
#314Seed-specific expression vector and its construction methods and applications
#315Diagnostic method for Alzheimer's disease
#316APOLIPOPROTEIN A-1 MIMIC PEPTIDES, AND THERAPEUTIC AGENT FOR TREATING HYPERLIPIDEMIA AND DISEASES RELATED TO HYPERLIPIDEMIA COMPRISING SAME
#317Oxidant resistant apolipoprotein A-1 and mimetic peptides
#318Apolipoprotein A1 Mimetics and Uses Thereof
#319Treatment of fungal and/or protist infections
#320Charged lipoprotein complexes and their uses
#321SYNTHETIC APOLIPOPROTEIN E MIMICKING POLYPEPTIDES AND METHODS OF USE
#322Compositions comprising apolipoprotein A polypeptide and interleukin 15, and methods of treatment using the same
#323LIPOPROTEIN COMPLEXES AND MANUFACTURING AND USES THEREOF
#324Prokaryotic expression construct
#325APOE immunotherapy
#326Fusion Protein of an Anti-CD20 Antibody Fab Fragment and Lidamycin, a Method for Preparing the Same, and the Use Thereof
#327Tetranectin-apolipoprotein A-I, lipid particles containing it and its use
#328METHOD FOR PRODUCING A LIPID PARTICLE, THE LIPID PARTICLE ITSELF AND ITS USE
#329Manufacturing and Purification Processes of Complex Protein found in Fraction IV to make a separated Apo, Transferrin , and Alpha 1 Anti strepsin (A1AT) or A combined Transferrin / Apo/Human Albumin/A1AT and all new found proteins
#330PEGYLATED HUMAN APOA-1 AND PROCESS FOR PRODUCTION THEREOF
#331Multi-domain amphipathic helical peptides and methods of their use
#332Polymer-von Willebrand factor-conjugates
#333Inhibition of ApoE Cleavage Activity in the Treatment of ApoE-Related Disorders
#334APOLIPOPROTEIN L- I VARIANTS AND THEIR USE
#335PEPTIDE-MEDIATED NON-COVALENT DELIVERY OF ACTIVE AGENTS ACROSS THE BLOOD-BRAIN BARRIER
#336Anti-trypanosomal peptides and uses thereof
#337PEPTIDE-BASED PASSIVE IMMUNIZATION THERAPY FOR THE TREATMENT OF ATHEROSCLEROSIS
#338Assays for Differentiating between Ischemic and Hemorrhagic Stroke in a Human Patient
#339METHODS FOR THE PRODUCTION OF APOLIPOPROTEINS IN TRANSGENIC PLANTS
#340NON-NATURALLY OCCURRING LIPOPROTEIN PARTICLE
#341Treatment of subarachnoid hemorrhage with ApoE analogs
#342Expression of apoAI and variants thereof using spliceosome mediated RNA -splicing
#343Orally administered peptides synergize statin activity
#344G-TYPE PEPTIDES AND OTHER AGENTS TO AMELIORATE ATHEROSCLEROSIS AND OTHER PATHOLOGIES
#345Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
#346HDL particles for delivery of nucleic acids
#347ApoE analogs and methods for their use
#348PROTEIN ISOFORMS FOR DIAGNOSIS
#349Fusion proteins and related compositions, methods and systems for treatment and/or prevention of atherosclerosis
#350CONJUGATES FOR THE ADMINISTRATION OF BIOLOGICALLY ACTIVE COMPOUNDS
#351Expression of factor IX in gene therapy vectors
#352Synthetic peptides, methods and kits for diagnosing autoimmune diseases
#353Compositions and Methods for Treating Atherosclerosis
#354Sustained release of APO A-I mimetic peptides and methods of treatment
#355Compositions and methods for solubilizing membrane proteins without the use of detergent
#356Peptide derivatives and use thereof as carriers for molecules in the form of conjugates
#357Therapeutic compositions
#358BLADDER CANCER BIOMARKER AND TEST METHOD USING THE SAME
#359SALICYLANILIDE MODIFIED PEPTIDES FOR USE AS ORAL THERAPEUTICS
#360Class of therapeutic protein based molecules
#361Modified Human Apolipoprotein A-1 and Their Uses
#362METHODS OF TREATING CANCER WITH APOE PEPTIDES
#363FIBROMYALGIA TEST METHOD
#364Polymer-von Willebrand factor-conjugates
#365Methods for purification of alpha-1-antitrypsin andapolipoprotein A-1
#366METHODS AND SYSTEMS FOR PRODUCING NANOLIPOPROTEIN PARTICLES
#367Therapeutic compositions
#368APOA-1 PEPTIDE MIMETICS
#369Polypeptide inhibiting angiogenesis and application thereof
#370Peptides promoting lipid efflux
#371TRYPANOSOME RESISTANT NON-HUMAN TRANSGENIC ANIMAL
#372TRPM-2 antisense therapy
#373Methods of suppressing microglial activation
#374ANTI-OBESE IMMUNOGENIC HYBRID POLYPEPTIDES AND ANTI-OBESE VACCINE COMPOSITION COMPRISING THE SAME
#375Biochemical markers for CVD risk assessment
#376Clusterin derived peptide
#377Methods of inhibiting calcineurin with ApoE analogs
#378Synthetic apolipoprotein E mimicking polypeptides and methods of use
#379Synthetic apolipoprotein E mimicking polypeptides and methods of use
#380Compositions and methods for treating atherosclerosis
#381Apolipoprotein A-I mimics
#382Models of atherosclerosis, hyperlipidemia, lipoprotein oxidation and blood vessel inflammation and methods for making and using them
#383Therapeutic compositions
#384PEPTIDES AND PEPTIDE MIMETICS TO INHIBIT THE ONSET AND/OR PROGRESSION OF FIBROTIC AND/OR PRE-FIBROTIC PATHOLOGIES
#385Anti-obese immunogenic hybrid polypeptides and anti-obese vaccine composition comprising the same
#386PEPTIDES AND PEPTIDE MIMETICS TO TREAT CANCER
#387Protease-sensitive site in apolipoprotein A1, therapeutic and diagnostic implications
#388TREATMENT OF VIRAL INFECTIONS
#389Cosmetic use of apolipoprotein D type proteins
#390USE OF N-TERMINAL AND C-TERMINAL PROTEOMICS TECHNOLOGY TO ENHANCE PROTEIN THERAPEUTICS AND DIAGNOSTICS
#391HELICAL SYNTHETIC PEPTIDES THAT STIMULATE CELLULAR CHOLESTEROL EFFLUX
#392Method of treating or inhibiting inflammation by multi-domain amphipathic helical peptides
#393FUSION PROTEIN OF IMMUNOGLOBULIN FC AND HUMAN APOLIPOPROTEIN(A) KRINGLE FRAGMENT
#394PEPTIDE EPITOPES OF APOLIPOPROTEIN B
#395In-plant production of oligomeric (comprising three or more units) forms of human Apo A-1 protein muteins
#396Methods for decreasing set in inhibiting protein phosphatase 2A (PP2A) and/or increasing the activity of cyclin-dependent kinase 5 (CDK5) by an APOE peptide
#397Treatment of apolipoprotein-A1 related diseases by inhibition of natural antisense transcript to apolipoprotein-A1
#398CYSTEINE-CONTAINING PEPTIDES HAVING ANTIOXIDANT PROPERTIES
#399Immunogenic lipopeptides comprising T-helper and B-cell epitopes
#400Apolipoprotein A1 mimetics and uses thereof
#401Antibodies against a peptide epitope of apolipoprotein B
#402Method of purifying apolipoprotein A-1
#403Antibodies against a peptide epitope of apolipoprotein B
#404Isolated nucleic acid molecule encoding a peptide or peptide analog comprising the SEQ ID No. 3
#405Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
#406Membrane Scaffold Proteins
#407PEPTIDE-BASED IMMUNIZATION THERAPY FOR TREATMENT OF ATHEROSCLEROSIS
#408Antibodies against a peptide epitope of apoliporotein B
#409COMPOSITION AND METHOD FOR CLUSTERIN-MEDIATED STEM CELL THERAPY FOR TREATMENT OF ATHEROSCLEROSIS AND HEART FAILURE
#410Antibodies against a peptide epitope of apolipoprotein B
#411Antibodies against a peptide epitope of apoliprotein B
#412EXPRESSION OF ORPHAN GPR64 IN INFLAMMATORY DISEASES
#413Methods of suppressing microglial activation and systemic inflammatory responses
#414Novel apolipoprotein gene involved in lipid metabolism
#415METHODS OF SUPPRESSING MICROGLIAL ACTIVATION AND SYSTEMIC INFLAMMATORY RESPONSES
#416Low-Density Lipoprotein Receptor-Related Protein 2 Clears Amyloid-Beta Peptide A cross the Blood-Brain Barrier via Apolipoprotein J
#417Peptide-based passive immunization therapy for treatment of atherosclerosis
#418Oxidant resistant apolipoprotein A-1 and mimetic peptides
#419Vascular Aging-Predicting Factor and Utilization of the Same
#420METHODS AND SYSTEMS FOR MONITORING PRODUCTION OF A TARGET PROTEIN IN A NANOLIPOPROTEIN PARTICLE
#421APOLIPOPROTEIN ANALOGUES
#422Treatment of subarachnoid hemorrhage with Apo E analogs
#423Peptide epitopes of apolipoprotein B
#424PEPTIDE EPITOPES OF APOLIPOPROTEIN B
#425Glycated peptides and methods of use
#426Glycoprotein and apolipoprotein biopolymer markers predictive of Alzheimers disease
#427PEPTIDE-BASED IMMUNIZATION THERAPY FOR TREATMENT OF ATHEROSCLEROSIS
#428COMPOSITIONS AND METHODS FOR TREATING DISEASES
#429Sustained release of Apo A-I mimetic peptides and methods of treatment
#430Methods and Compositions Related to APOBEC-1 Expression
#431Treatment of viral infections
#432TISSUE FACTOR COMPOSITIONS AND METHODS
#433APO E analogs and methods for their use
#434Methods for identifying agents for treating cardiovascular disease using inhibition of myeloperoxidase binding
#435APOLIPOPROTEIN E STABLE FOLDING INTERMEDIATE AND METHODS OF USE THEREOF
#436Nucleic acid encoding apolipoprotein E-I3
#437Peptide epitopes of apolipoprotein B
#438Apparatus for measuring high density lipoproteins and method of separating high density lipoproteins
#439COMPOSITIONS AND METHODS FOR PRODUCING APOLIPOPROTEIN
#440Methods for treating vascular disease
#441Peptide epitopes of apolipoprotein B
#442Use of Eotaxin as a Diagnostic Indicator For Atherosclerosis and Vascular Inflammation
#443Peptide epitopes of apolipoprotein B
#444Peptides and their use in assays for cardiovascular disease
#445Peptides that promote lipid efflux
#446Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
#447Mutant apolipoprotein A-1 polypeptide with increased resistance to oxidation and reactive carbonyls
#448Methods and Apparatus for Creating Particle Derivatives of HDL with Reduced Lipid Content
#449Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
#450Novel Peptides that Promote Lipid Efflux
#451Compositions and Methods for Treating Atherosclerosis
#452Method of treating a patient suffering from a bleeding disorder comprising administering an antibody against the A3-C1 of FVIII
#453Methods and Apparatus for Creating Particle Derivatives of HDL with Reduced Lipid Content
#454Treatment of Fungal and/or Protist Infections
#455Novel Peptides That Promote Lipid Efflux
#456Novel Peptides That Promote Lipid Efflux
#457Complementary Peptides For Beta-Amyloid 29-42 Peptide
#458Genetically engineered and phenotyped mice and stem cell clones for producing the same
#459ASSAY FOR DIABETES
#460Expression of factor IX in gene therapy vectors
#461Methods of suppressing microglial activation
#462Novel Peptides That Promote Lipid Efflux
#463Peptides for treatment of scleroderma
#464Orally administered peptides synergize statin activity
#465ORALLY ADMINISTERED PEPTIDES SYNERGIZE STATIN ACTIVITY
#466Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
#467Antibody immunization therapy for treatment of atherosclerosis
#468Mouse model of chronic heart failure and coronary atherosclerosis regression
#469PEPTIDE-BASED IMMUNIZATION THERAPY FOR TREATMENT OF ATHEROSCLEROSIS
#470Methods and compositions for treating hypercholesterolemia
#471TRPM-2 antisense therapy
#472Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
#473Gene Therapy Approaches to Supply Apolipoprotein A-I Agonists and Their Use to Treat Dyslipidemic Disorder
#474Orally administered peptides synergize statin activity
#475MODEL FOR NEURODEGENERATIVE DISEASES INVOLVING AMYLOID ACCUMULATION
#476APO-A-I Regulation of T-Cell Signaling
#477Methods of discovering chemicals capable of functioning as gene expression modulators
#478ANTIBODY IMMUNIZATION THERAPY FOR TREATMENT OF ATHEROSCLEROSIS
#479Therapeutic compositions
#480Orally administered peptides synergize statin activity
#481Valency platform molecules comprising aminooxy groups
#482Apolipoprotein biopolymer markers indicative of insulin resistance
#483Peptide/Lipid Complex Formation by Co-Lyphilization
#484Use of clusterin for the treatment and/or prevention of peripheral neurological diseases
#485Antiviral polypeptides comprising tandem repeats of APOE 141-149 and variants thereof
#486Assay for diabetes
#487Synthetic single domain polypeptides mimicking apolipoprotein E and methods of use
#488Transgenic mice carrying the HP-2 gene and uses as models for vascular diseases
#489Antibodies against a peptide epitope of apolipoprotein B
#490Peptide-based passive immunization therapy for treatment of atherosclerosis
#491Immunogenic lipopeptides comprising T-helper and B-cell epitopes
#492Orally administered small peptides synergize statin activity
#493Compositions and Methods for Producing Apolipoprotein Gene Products in Lactic Acid Bacteria
#494Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
#495Therapeutic agent for treatment of cancer comprising human apolipoprotein (a) kringles lk68 or lk8 genes as effective ingredient, and method for treating cancer using the same
#496Ligand-binding reagents for quenching and improved purification of lipidated proteins
#497Muteins of apolipoprotein D
#498Method for separating and concentrating biological materials using continuous-flow ultracentrifugation
#499Cysteine-containing peptides having antioxidant properties
#500Cysteine-containing peptides having antioxidant properties
#501G-type peptides to ameliorate atherosclerosis
#502Multimeric apoprotein agonists
#503Peptide-based immunization therapy for treatment of atherosclerosis
#504Gene-targeted animal model of apolipoprotein E4 domain interaction and uses thereof
#505Constructs binding to phosphatidylserine and their use in disease treatment
#506Charged lipoprotein complexes and their uses
#507Nitrosated and nitrosylated heme proteins
#508Protein biopolymer markers predictive of insulin resistance
#509Protein biopolymer markers predictive of insulin resistance
#510Protein biopolymer markers predictive of insulin resistance
#511Protein biopolymer markers predictive of insulin resistance
#512G-type peptides and other agents to ameliorate atherosclerosis and other pathologies
#513Protein biopolymer markers predictive of insulin resistance
#514Expression of apoAI and variants thereof using spliceosome mediated RNA trans-splicing
#515Expression of apoA-1 and variants thereof using spliceosome mediated RNA trans-splicing
#516Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
#517Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia
#518Polymer-factor VIII-von Willebrand factor-conjugates
#519Oxidised fragments of apolioprotein B and their uses
#520Compounds and methods for lowering cholesterol levels without inducing hypertrigylceridemia
#521Valency platform molecules comprising aminooxy groups
#522Compositions and methods for treating atherosclerosis
#523Method of predicting genetic risk for hypertension
#524Clusterin-mediated inhibition of apoptosis via stromal bone marrow cell delivery to a cardiac site
#525Tissue factor compositions and methods
#526Methods and compositions for treating hypercholesterolemia
#527Therapeutic agents and methods for cardiovascular disease
#528Apolipoprotein A1 mimetics and uses thereof
#529Full-length human cdnas encoding potentially secreted proteins
#530Apolipoprotein A-I derivatives with altered immunogenicity
#531Methods of suppressing microglial activation
#532ProapolipoproteinA-I mutant and pharmaceutical composition comprising the same for prevention and treatment of atherosclerosis and hyperlipidemia
#533Novel nucleic acids and polypeptides
#534Non-human animal models of atherosclerosis and methods of use thereof
#535Animal model for raising HDL-cholesterol with niacin
#536Longevity and PAPP-A
#537Inducible heart attack animal model
#538Compositions and methods for treating diseases
#539Lipoproteins as nucleic acid vectors
#540Multimeric Apo A-I agonist compounds
#541Method of producing an anticoagulation effect
#542Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
#543Helical synthetic peptides that stimulate cellular cholesterol efflux
#544Vaccines
#545Membrane scaffold proteins
#546Methods for the production of apolipoproteins in transgenic plants
#547Orally administered small peptides synergize statin activity
#548Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia
#549Compositions and methods for apo-b48 and apo-b100 assay
#550Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
#551Method of producing apolipoprotein analogues
#552High bone mass gene of 11q13.3
#553Synthetic peptides and kits for diagnosis of anti-phospholipid syndrome
#554Muteins of apolipoprotein D
#555Lipoproteins as nucleic acid vectors
#556Methods of prevention and treatment using apolipoprotein analogues
#557Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
#558Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
#559GSSP4 polynucleotides and polypeptides and uses thereof
#560Transgenic mouse lacking PAPP-A activity
#561Therapeutic and diagnostic domain 1 beta2GP1 polypeptides and methods of using same
#562Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
#563Use of remnant lipoprotein in the treatment and prevention of cardiovascular disease
#564Detection apparatus for differential-charged particle mobility analyzer